Intellectual Property India Publishes Patent Application for 'Modified Rhabdovirus Glycoproteins And Uses Thereof' Filed by Regeneron Pharmaceuticals, Inc.; and Vyriad, Inc.

MUMBAI, India, Sept. 12 -- Intellectual Property India has published a patent application (202517079780 A) filed by Regeneron Pharmaceuticals, Inc.; and Vyriad, Inc., Tarrytown, U.S.A., on Aug. 22, for 'modified rhabdovirus glycoproteins and uses thereof.'

Inventor(s) include Buehler, Jason; Russell, Stephen J.; Nenavath, Gopal Naik; Moy, Melissa; Ziegler, Chris; and Vandergaast, Rianna.

The application for the patent was published on Sept. 12, under issue no. 37/2025.

According to the abstract released by the Intellectual Property India: "The present disclosure provides recombinant fusogenic proteins comprising a rhabdovirus glycoprotein (G) and a targeting molecule attached to the N-terminus of the rhabdovirus glycoprotein. Further provided are related recombinant polynucleotides, host cells, and pharmaceutical compositions. Recombinant viruses, e.g., recombinant pseudotyped viruses, and cell-derived nanovesicles comprising the recombinant polynucleotides are also provided. Further provided are methods for using the recombinant fusogenic proteins, polynucleotides, viruses, and cell-derived nanovesicles, and/or pharmaceutical compositions thereof, including their use in the treatment of cancer."

The patent application was internationally filed on Jan. 26, 2024, under International application No.PCT/US2024/013058.

Disclaimer: Curated by HT Syndication.